Oncopeptides AB (Oncopeptides AB) Debt-to-Equity : 2.22 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Oncopeptides AB Debt-to-Equity?

Oncopeptides AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. Oncopeptides AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $12.30 Mil. Oncopeptides AB's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $5.54 Mil. Oncopeptides AB's debt to equity for the quarter that ended in Dec. 2023 was 2.22.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Oncopeptides AB's Debt-to-Equity or its related term are showing as below:

ONPPF' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.03 Max: 2.22
Current: 2.22

During the past 10 years, the highest Debt-to-Equity Ratio of Oncopeptides AB was 2.22. The lowest was 0.02. And the median was 0.03.

ONPPF's Debt-to-Equity is ranked worse than
95.59% of 1066 companies
in the Biotechnology industry
Industry Median: 0.145 vs ONPPF: 2.22

Oncopeptides AB Debt-to-Equity Historical Data

The historical data trend for Oncopeptides AB's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncopeptides AB Debt-to-Equity Chart

Oncopeptides AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.02

0.03

0.07

0.03

2.22

Oncopeptides AB Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.03	-	0.62	0.81	2.22

Competitive Comparison of Oncopeptides AB's Debt-to-Equity

For the Biotechnology subindustry, Oncopeptides AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oncopeptides AB's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncopeptides AB's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Oncopeptides AB's Debt-to-Equity falls into.

Oncopeptides AB Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Oncopeptides AB's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	12.299)	/	5.535
	=	2.22

Oncopeptides AB's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	12.299)	/	5.535
	=	2.22

Oncopeptides AB (OTCPK:ONPPF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Oncopeptides AB Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Oncopeptides AB's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncopeptides AB (Oncopeptides AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncopeptides AB (OTCPK:ONPPF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

ONCO:Sweden 0RN4:UK OND:Germany OND:Germany

Address

Vastra Tradgardsgatan 15, Stockholm, SWE, SE-111 53

Website

https://www.oncopeptides.com

Oncopeptides AB is a biotech company focused on the research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It has focused on the development of the product candidate melflufen (Ygalo), a peptide-conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Compounds. Melflufen is intended as an effective treatment for hematological cancers and in particular multiple myeloma.